G
Gemini Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2015
Innovative therapies targeting genetically defined subpopulations in dry AMD and related diseases MoreLess
Gemini Therapeutics is a biotechnology company focused on developing precision medicines for genetically defined subpopulations affected by dry age-related macular degeneration (AMD) and related diseases. The company operates in the biopharmaceutical market, targeting common but poorly understood heterogeneous diseases. Gemini Therapeutics employs a therapeutic approach that leverages recombinant proteins, gene therapy, and monoclonal antibodies to create effective treatments. The business model revolves around identifying specific therapeutic candidates through scientific insights and conducting natural history studies to define target populations. Revenue is generated through the development and commercialization of these targeted therapies. The company serves patients suffering from dry AMD and related conditions, aiming to bring better medicine to millions of people worldwide. Keywords: precision medicine, dry AMD, gene therapy, monoclonal antibodies, recombinant proteins, biopharmaceutical, therapeutic candidates, genetically defined subpopulations, heterogeneous diseases, natural history studies.
Company overview
Gemini Therapeutics company information
The essential company record, classifications and operating signals in one place.
Valuation & funding
Gemini Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Feb 2021 | $0 | — | Undisclosed | — |
| SERIES A✓Equity / VC | Oct 2017 | $43M | $170M | Atlas Venture · OrbiMed · Lightstone Ventures | — |
| SEED✓Equity / VC | Apr 2016 | $2M | $8M | Atlas Venture · OrbiMed · Lightstone Ventures | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 1 |
| 2025 | 1 |
| 2024 | 36 |
| 2023 | 36 |
| 2022 | 36 |
| 2021 | 39 |
| 2020 | 34 |
Growth signals
Gemini Therapeutics website traffic
Latest recorded traffic for Gemini Therapeutics is 210 monthly website visits, down 83.8% over the last three months. Gemini Therapeutics's team grew 0% over the past year.
Comparisons
Gemini Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Gemini Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Gemini Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Gemini Therapeutics has talent and traffic
In the news
Latest news about Gemini Therapeutics
Recent press, funding announcements, and product moves mentioning Gemini Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Gemini Therapeutics
An AI-synthesized read of the highest-engagement posts about Gemini Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gemini Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.